To gain insight into the overall transcriptional differences in the tumor and immune microenvironments, we performed bulk tumor RNA-Seq on an independent cohort of p53/MCA tumors harvested 6 days after RT and 3 days after CpG treatment or their respective controls. The gene discussed is TP53; the disease is neoplasm.